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Teaser This review provides the latest findings regarding the application of CRISPR/Cas9 for
the identification of new therapeutic targets and associated major challenges in cancer
treatment.
CRISPR/Cas9: a powerful tool for
identification of new targets for
cancer treatment
Bin Liuz, Ali Saberz and Hidde J. Haisma
Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of
Groningen, The Netherlands
Clustered regularly interspaced short palindromic repeats (CRISPR)/
CRISPR associated nuclease 9 (Cas9), as a powerful genome-editing tool,
has revolutionized genetic engineering. It is widely used to investigate the
molecular basis of different cancer types. In this review, we present an
overview of recent studies in which CRISPR/Cas9 has been used for the
identification of potential molecular targets. Based on the collected data,
we suggest here that CRISPR/Cas9 is an effective system to distinguish
between mutant and wild-type alleles in cancer. We show that several new
potential therapeutic targets, such as CD38, CXCR2, MASTL, and RBX2, as
well as several noncoding (nc)RNAs have been identified using CRISPR/
Cas9 technology. We also discuss the obstacles and challenges that we face
for using CRISPR/Cas9 as a therapeutic.
Introduction
The accumulation of genetic mutations in cells over time leads to cancer. In addition, certain
gene changes, such as driver mutations in TP53, EGFR, KRAS, BRAF, HER2, and MET, can make a
cell cancerous. Treatment strategies are conventionally based on histological subtypes. However,
in addition to the conventional histological classifications, each cancer type can now be
subdivided into various molecular subtypes that have a crucial role in the treatment decision-
making process. Each molecular subtype is treated differently and clinicians can also predict
treatment outcomes and patient survival. For instance, patients with lung cancer with EGFR-
activating mutations are treated with different types of tyrosine kinase inhibitor (TKI), such as
gifitinib, erlotinib, or afatinib, depending on the mutation. Yet, resistance to the TKIs inevitably
emerges either by DNA mutations or/and metabolic changes. As a result, treatment strategies are
modified based on the new molecular signature. However, eventually, the tumor cells do not
respond to any treatment [1]. Therefore, identification of new therapeutic targets to improve
patient survival and clinical outcomes is crucial [2,3].
In recent years, CRISPR/Cas9 has significantly influenced the field of molecular biology and
gene therapy. Solid tumors are the most common type of tumors, but less progress has been made
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I/II Active NCT03044743for gene therapy-based treatment compared with nonsolid
tumors, such as leukemia. However, this situation is rapidly
changing with developments in CRISPR/Cas9. There is a growing
amount of promising preclinical data showing CRISPR/Cas9 to be
an effective tool to specifically target cancer cells and suppress
tumor growth [4–6]. This could lead to the discovery of novel
molecular targets for cancer treatment.
There is an increasing number of clinical trials utilizing CRISPR/
Cas9 technology to treat cancers of different origin (Table 1). Most
of these trials are based on genetically engineered T cells for cancer
immunotherapy, rather than targeting a specific gene in the tumor
cells themselves. One of the main problems associated with the
direct targeting of cancer is the lack of an effective and safe delivery
method that can be used in patients. Tumor heterogeneity is
another issue that might be a challenge because tumors usually
comprise different subclones (i.e., intratumor heterogeneity) [7–
10]. Thus, even with the right delivery system, outgrowth of a
minor subclone can emerge and the treatment would no longer be
effective. Nonetheless, identification of different major subclones
before treatment and recruitment of multiple Cas9/guide (g)RNA
might be an option to minimize relapse in patients.
Here, we provide an overview of studies in which CRISPR/Cas9
has been utilized for the identification of potential therapeutic
targets in some of the most frequent solid tumors, including lung,
breast, brain, liver, and colorectal cancer. We discuss potential
candidates for therapy that are either highly expressed or activated
in different cancer types, because they are more convenient to
inhibit or disrupt. We end by presenting recent advances in, and
different delivery methods for, CRISPR/Cas9.
CRISPR/Cas9 gene-editing technology
CRISPR/Cas9 is a recently discovered, powerful gene-editing tool
derived from a prokaryotic defense system [11–14]. This technol-
ogy has enabled researchers to edit the genome of eukaryotic cells
more precisely and efficiently compared with previous methods,
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interle956 www.drugdiscoverytoday.comsuch as zinc-finger nucleases (ZFNs) and transcription activator-
like effector nucleases (TALENs) [15].
The structure of CRISPR/Cas9
The structure of CRISPR/Cas9 has comprehensively been described
elsewhere [15–17]. The CRISPR/Cas9 system has three compo-
nents; a single guide RNA (sgRNA), which is specific to a target
sequence of DNA; Cas9 protein with DNA endonuclease activity;
and a tracrRNA that interacts with Cas9 (Fig. 1). The gRNA (ap-
proximately 20 base pairs in length) binds to the target site in the
genome and directs the Cas9 protein. The Cas9 protein is a RNA-
guided nuclease that was discovered in the CRISPR type II adaptive
immunity system of Streptococcus pyogenes and it is responsible for
cleaving double-strand DNA [17].
gRNAs and their specificity
Several factors, such as sequence, length, and secondary structure,
of gRNAs can influence their efficiency and specificity [18,19]. In
addition, the efficiency of the CRISPR/Cas9 complex can be influ-
enced by other factors, including the genomic locus of the target,
chromatin accessibility, nucleosomes, and other components
around gRNA-binding sites [19]. The gRNA sequence has a crucial
role in the efficiency, specificity, and accuracy of CRISPR/Cas9-
mediated genome editing. The first 10–12 nucleotides at the 30 end
of gRNA, immediately adjacent to a protospacer adjacent motif
(PAM), called the ‘seed sequence’, bind to the target sequence and
determine the specificity [18,20]. Truncated gRNAs with shorter
complementary nucleotides ( <20) can reduce off-target effects by
5000-fold without sacrificing on-target efficiency [21]. Moreover,
extending the gRNA duplex by 5 base pairs can significantly
improve the knockout efficiency [22].
CRISPR-associated nucleases
Different versions of CRISPR-associated nucleases are currently
under development, greatly expanding the CRISPR-based toolbox
for genome editing (Table 2). Cpf1 is an RNA-guided endonuclease
that belongs to the class 2 CRISPR-Cas system, the same as Cas9
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FIGURE 1
Schematic picture of genome editing mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated nuclease 9 (Cas9), and
DNA repairing. The Cas9 protein, which is guided by a desired single-strand guide RNA (gRNA), cuts the double-stranded DNA and makes a double strand break

















W[23]. However, Cpf1 has different features compared with Cas9. For
example, it has only one single nuclease domain and a shorter
gRNA. Creating staggered cuts is one of the main characteristic
features of Cpf1. This type of cut is important for introducing
exogenous DNA into the genome by the homology directed repair
(HDR) pathway. In addition, Cpf1 has both endoribonuclease and
endonuclease activities, which is unique for a nuclease [24]. These
properties make Cpf1 both a complex and effective genome-edit-
ing tool for gene targeting and gene silencing. C2C2 is another
member of class 2 type VI-A CRISPR-Cas and was found in Lepto-
trichia shahii, where it protects the bacterium against RNA phages.
C2C2 can be used to target and regulate RNAs. It has two RNase
catalytic pockets with dual RNase activities, which can be recruited
for the identification of cellular transcripts [25]. The structure and
function of C2C2 is unique and provides a novel tool for RNA
manipulation [25–27].
Precisely editing a single base in the genome without introduc-
ing double-stranded breaks (DSBs) was a longstanding goal that,
with engineered Cas9 base editors, is now possible. The ‘base
editors’ comprise fusions of a dead Cas9 domain and a cytidine
deaminase enzyme that is able to convert GC to AT without
introducing DSBs [28]. Recently, researchers created a Cas9 fused
with a transfer RNA adenosine deaminase that can mediate con-
version of AT to GC [29]. These base editors are valuable tools for
repairing disease-related mutations.Advantages of CRISPR/Cas9 over ZFN and TALENs
The CRISPR/Cas9 system has several advantages over ZFN and
TALENs in terms of its simplicity, flexibility, and affordability. The
most important difference is that the CRISPR system relies on
RNA–DNA recognition, rather than on the protein–DNA-binding
mechanism [11,17,30]. Thus, it is more ‘doable’ and easier to
construct a customized CRISPR/Cas9 complex by only changing
the gRNA sequence instead of engineering a new protein. The
target sequence needs to be immediately upstream of a PAM
sequence (50-NGG-30) [17], because the latter is essential for target
recognition by Cas9. This short sequence occurs approximately
once every eight base pairs in the human genome, which makes it
possible to design several gRNAs for one specific target gene [31].
Targeting cancer-related genes and identification of
potential therapeutic targets in solid tumors
CRISPR/Cas9 is routinely used in research laboratories because of
its simplicity and efficiency. In addition, the cost of this gene-
editing tool is reducing daily. The CRISPR/Cas9 gene-editing
technology helped researchers to identify the role of different
genes in cancer; for instance whether they function as oncogenes
or tumor genes [32–36]. Several groups generated in vitro and in vivo
knockout models to study the molecular basis of different cancer
types [37–39]. CRISPR/Cas9 is also widely used for inducing spe-
cific mutations in certain genes to explore the potential causativewww.drugdiscoverytoday.com 957
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IEWrole of these mutations in disease development. In addition,
CRISPR barcoding technology can be used to investigate tumor
heterogeneity [40,41]. Moreover, genome-wide CRISPR/Cas9
screening is frequently used to identify potential therapeutic
targets in different cancers. Here, we mainly focus on new poten-
tial molecular targets that have been identified by using CRISPR/
Cas9 in some of the most frequent solid tumors, including lung,
breast, brain, liver, and colorectal cancers.
Lung cancer
Lung cancer is the leading cause of cancer-related death worldwide.
Non-small cell lung cancer (NSCLC) subtypes account for 85% of
all lung cancers [42]. The identification of specific genetic aberra-
tions is important to choose the appropriate treatment strategy,
particularly in patients with adenocarcinoma. Currently, several
molecular targets, such as EGFR, BRAF, ALK-EML4, and cMET, are
clinically available for the treatment of NSCLC. However, treatment
options are limited by the number of molecular targets and by
emerging drug resistance [1,42]. In recent years, CRISPR/Cas9-based
in vitro and in vivo studies of lung cancer have identified new
treatment strategies and potential therapeutic targets.
Targeting the mutant version of certain genes using the CRISPR/
Cas9 gene-editing system can specifically target mutant cancer
cells, but not normal cells. Targeting the mutant version of the
EGFR gene (L858R) resulted in the selective elimination of mutant
cells and reduced cell proliferation both in vitro and in vivo [43]. In
another study, Koo et al. selectively abrogated EGFR mutant alleles
(L858R) in a NSCLC cell line (H1975) using an adenovirus (AdV)
vector that resulted in cancer cell death and significantly reduced
tumor size in vivo [4]. These findings underscore the potential of
CRISPR-based therapeutics in tumor-specific targeted therapy and
in distinguishing normal from mutant tumor cells.
Approximately 30% of patients with lung cancer have somatic
activating KRAS mutations. Currently, there is no effective treat-
ment for KRAS mutant lung tumors, which are considered as
undruggable. CRISPR-based deletion of murine Kras in two differ-
TABLE 2
CRISPR-associated nucleases
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RNA editors Cas13a/Cas13b/Cas13d Targeting RNA rather 958 www.drugdiscoverytoday.coment KrasG12D/1/p53/ lung cancer cell lines resulted in a significant
reduction in cell proliferation, but the cells were still viable and
sustained their ability to form tumors in vivo. Transcriptome
sequencing revealed a substantially higher expression of Fas re-
ceptor in the knockout cells. Interestingly, an activating Fas re-
ceptor antibody selectively induced apoptosis in these Kras/
lung cancer cells [44]. Oncogenic Ras can inhibit Fas ligand-
mediated apoptosis through downregulation of Fas [45]; therefore,
simultaneous inhibition of KRAS and activation of FAS might be
an effective therapeutic approach against KRAS-driven lung cancer
tumors.
CD38 is a glycoprotein that functions as both an ADP-ribosyl
cyclase and a NAD glycohydrolase. Its expression level is negative-
ly associated with poor prognosis in patients with chronic lym-
phocytic leukemia and it is used as a therapeutic target in multiple
myeloma [46,47]. However, its role is solid tumors, such as lung
cancer, is not clear. CRISPR-based deletion of CD38 in a lung
adenocarcinoma cell line (A549) resulted in substantial suppres-
sion of cell growth and invasion in vitro and in xenografts in mice,
suggesting CD38 as a potential target in lung cancer. Further
investigations unraveled an elevated level of CD38 in 93% (27/
29) of lung cancer cell lines and 40% (11/27) of NSCLC primary
tumors. Hence, direct disruption of this target through monoclo-
nal antibodies, such as daratumumab, might be effective in
patients with NSCLC with CD38 overexpression [48].
Disruption of focal adhesion kinase (FAK), a nonreceptor tyro-
sine kinase that is frequently amplified in lung cancer cell lines,
results in DNA damage and sensitivity to ionizing radiation. In
addition, using CRISPR/Cas9 approaches, the presence of FAK was
shown to be crucial for the oncogenic and clonogenic abilities of
KRAS mutants in tumor xenografts [49,50]. In addition, FAK is
significantly overexpressed in patients with NSCLC and is associ-
ated with poorer clinical outcomes [51–53], which make it an
attractive target to treat NSCLC and prevent distant metastasis.
TAZ is a coactivator of the Hippo pathway and is upregulated in
lung cancer. Dual inactivation of TAZ and YAP (a transcriptional

















Wactivator) suppressed cell proliferation as well as cancer stem cell
(CSC) sphere formation in lung cancer, suggesting them as potential
molecular targets [54]. CRISPR-based disruption of oncogenic
MUC1-C hindered the growth of KRAS-dependent lung adenocarci-
noma cells (i.e., A549 and A460) [55]. In addition, overexpression of
MUC1 has been shown in >80% of NSCLCs and is associated with
poor prognosis [56,57]. It also has a role in epithelial-mesenchymal
transition (EMT) and self-renewal ability, each of which are drug
resistance mechanisms in cancer [58,59]. Thus, suppression of
MUC1-C might delay resistance or even prevent tumor recurrence.
Likewise, it has been reported that overexpression of TNC, an
extracellular matrix (ECM) protein, is associated with lung cancer
recurrence [60]. CRISPR-based transcriptional activation of Tnc led
to metastatic dissemination of lung adenocarcinoma cells in vivo.
This highlights the central role of EMC-related proteins in metastasis
and their potential use as recurrence and metastasis biomarkers as
well as therapeutic targets in NSCLCs [61].
Chromatin-remodeling genes are frequently mutated, mostly
inactivating mutations, in lung adenocarcinoma [62–64]. A recent
study used CRISPR technology to knockout Smarca4, Arid1a, or
Setd2 to investigate their role in lung tumorigenesis. Loss of Arid1a
and Setd2 resulted in the development of higher-grade tumors and
strong tumor progression in both early- and late-stage lesions,
respectively. By contrast, ablation of Smarca4 led to tumor devel-
opment, whereas it attenuated disease progression in vivo over
time [34]. Previously, it was shown that SMARCA4 inactivation
promotes NSCLC aggressiveness [65]. Nevertheless, loss-of-func-
tion mutations in SMARCA4 have been reported to increase tumor
cell sensitivity to the Aurora kinase A inhibitor VX-680 both in vitro
and in xenograft mouse models [66]. These discrepancies make it
challenging to decide whether SMARCA4 is an appropriate molec-
ular candidate for therapy. However, genetic disruption or chemi-
cal-based inhibition of SMARCA4 could be of benefit for patients
with more advanced NSCLC.
miRNAs have important roles in cells and their dysregulation
has been shown in various types of cancer [67]. A recent study
exploited CRISPR/Cas9-based gene activation technology to inves-
tigate the role of miRNAs located on 14q32 in lung cancer cells.
Overexpression of those miRNAs significantly elevated cell migra-
tion and invasion. Moreover, higher expression levels of mir-323b,
mir-487a, and mir-539 were associated with metastasis and poorer
prognosis in patients with lung adenocarcinoma, especially in
those who had never smoked [68]. Thus, these 14q32 miRNAs
might be potential targets to prevent tumor cell dissemination and
distant metastasis in patients with lung adenocarcinoma.
Overall, application of the CRISPR/Cas9 genome-editing system
in lung cancer has led to the identification of several potential
therapeutic targets. Both in vitro and in vivo studies have shown
promising results, especially in the suppression of distant metas-
tasis, which is the main cause of death of patients. In addition,
CRISPR/Cas9 can target specific oncogenic alleles of certain genes,
such as EGFR, which is an important step towards cancer gene
therapy.
Breast cancer
Breast cancer is the most common type of cancer and the leading
cause of cancer-related death in women worldwide [69]. It is
divided into various subtypes with distinct morphologies. Basedon the expression of estrogen receptor (ER), progesterone receptor
(PR), ERBB2 (HER2), p53, and Ki-67, it can be classified into four
main molecular subtypes: triple-negative/basal-like; the Her2-
enriched; luminal A; and luminal B [70]. ER-positive luminal
subtypes are the most common types of breast cancer (almost
70%) and resistance to endocrine therapies occurs in 30% of
these patients [71]. Therefore, finding new treatment options is
crucial, especially in the case of recurrence. Recent CRISPR-medi-
ated studies have led to the identification of potential therapeutic
targets in different breast cancer subtypes.
Distant metastasis is one of the main characteristics of late-stage
cancers and the main reason for cancer mortality. Identification of
new therapeutic targets could help to prolong patient survival and
improve their life quality. MLK3 is a member of the MAP3K family,
which is involved in signal transduction and activation of the
MAPK pathway. Abrogation of Mlk3 in murine triple negative
breast cancer (TNBC) 4T1 cells, which are highly metastatic, led
to suppression of cell invasion and migration [72]. In another
study, CRISPR-mediated depletion of CX3CR1, a protein involved
in the dissemination of tumor cells into blood vessels, in breast
cancer cells impaired lodging of the cancer cells to bone and led to
a reduction in the number of cancerous lesions in mice [73].
In a recent study by Liao and colleagues, deletion of Ubr5, a
member of the E3 ligase family, in a murine mammary TNBC
model resulted in the inhibition of tumor growth and distant
metastasis in vivo as well as the promotion of apoptosis and
necrosis through impairment of angiogenesis. The authors also
showed high expression levels of UBR5 in patients with TNBC,
which make this protein interesting for further investigation for
targeted therapy [74]. CRISPR-mediated knockout of CXCR2 (IL-8
receptor) in breast cancer cells, showed a significant reduction in
cell migration in vitro as well as a lower rate of lung metastasis in
vivo [75]. CXCR2 is a stem-like cell marker for TNBC and shows
significantly lower expression in this subtype compared with non-
TNBC [76]. It is also known that targeting CXCR2 improves the
chemotherapeutic response in lung cancer [77]. Thus, treatment of
patients with advanced non-TNBC with anti-CXCR2 drugs might
be beneficial. In addition, MARK4 and FERMT2 are other potential
targets related to breast cancer cell migration and metastasis that
have been identified by CRISPR/Cas9 [78–80].
Several research groups have functionally studied different
proteins with oncogenic effects that might be suitable for further
investigation as therapeutic targets in breast cancer. For instance,
microtubule-associated serine/threonine kinase-like (MASTL) is
involved in the DNA damage response and its overexpression
correlates with poor clinical outcomes in ER-positive breast cancer
[81,82]. CRISPR-based disruption of MASTL kinase reduced cell
proliferation in breast cancer cell lines and showed therapeutic
effects in vivo. Further MASTL expression analysis in human breast
primary tumors showed higher expression in tumor cells com-
pared with normal tissue. In addition, higher MASTL expression
was significantly associated with poorer prognosis and its abun-
dance was associated with higher histological grades, suggesting
its crucial role in the progression of breast cancer [83]. Hence,
inhibition of MASTL might suppress tumor growth in high-grade
breast tumors.
One study showed that the SRC family kinase (SFK) FYN and
protein tyrosine phosphatase N23 (PTPN23) have an importantwww.drugdiscoverytoday.com 959












IEWrole in breast cancer. Double knockout of PTPN23 and FYN using
CRISPR/Cas9 significantly attenuated cell growth in both Cal-51
cells (a TNBC cell line) and xenograft mouse models. The authors
also found that expression of PTPN23 was positively associated
with a better clinical outcome [84]. Moreover, FYN is implicated in
drug resistance and is highly expressed in resistant cell lines
compared with parental cells [85,86]. Thus, inhibition of FYN in
resistant patients with PTPN23 loss might be a suitable option to
improve clinical outcomes.
Loss of cyclin-dependent kinase 7 (CDK7) in different TNBC cell
lines substantially reduced cancer cell growth in these cells, but
not in non-TNBC cells [87]. However, elevated expression of CDK7
has been shown in primary breast cancer tissues and its expression
is negatively associated with tumor grade and size. In addition,
higher expression of CDK7 was associated with better outcome
[88]. There are some discrepancies between in vivo and patient-
based studies, which might be the result of differences in breast
cancer subtypes. Nevertheless, CDK7 might be a suitable target at
least for a subset of patients with breast cancer. Disruption of
SHCBP1, a member of the Src homolog and collagen homolog
family, in breast cancer cell lines inhibited cell proliferation and
promoted apoptosis. The authors also showed that SHCBP1 is
overexpressed in >60% of breast primary tumors and is associated
with poorer survival [89]. Thus, suppression of these proteins
might result in the inhibition of tumor growth in patients and
improve their survival.
Zheng et al. performed CRISPR screening for RNA-binding pro-
teins (RBP) involved in breast tumorigenesis. They showed that
PHD finger protein 5A (PHF5A) is a key splicing factor and its
knockout leads to suppression of cell proliferation, tumor forma-
tion, and cell migration in breast cancer cells. They also identified
an elevated expression level of PHF5A in primary breast cancer
samples and showed its inverse correlation with patient survival
[69]. This is similar to a recent report in primary lung adenocarci-
noma [90]. Interestingly, inhibition of PHF5A led to tumor growth
suppression in glioblastoma xenograft mice [91]. Thus, PHF5A
might be a suitable therapeutic candidate not only in breast
tumors, but also other types of cancer.
ncRNAs are also important in carcinogenesis and their dysre-
gulation can lead to cancer. Singh et al. revealed higher expression
of BC200, a long ncRNA (lncRNA) that regulates protein synthesis,
in ER-positive breast cancer primary tumors compared with ER-
negative ones. Genetic abrogation of BC200 in vitro (MCF7 cell
line) and in vivo led to reduced cell growth through expression of
Bcl-x, a proapoptotic protein [92]. In addition, ablation of miR-10b
significantly suppressed cell migration in metastatic breast cancer
cells (i.e., MDA-MB-231) [93]. These data suggest that genetic
suppression of specific ncRNAs with a role in important signaling
pathways in tumor cells is a good therapeutic option for the
treatment of breast cancer.
In general, breast cancer preclinical studies have led to the
identification of several genes and proteins, the inhibition of
which might significantly improve treatment outcomes.
Gliomas
Malignant glioma is the most frequent form of brain primary
tumors. Based on WHO guidance, it is classified into astrocytomas,
ependymomas, oligoastrocytomas, and oligodendrogliomas. The960 www.drugdiscoverytoday.comgrade of malignancy varies from one subtype to another. For
instance, oligodendrogliomas and oligoastrocytomas are catego-
rized as grade II and III, respectively, whereas astrocytomas com-
prise four different grades (I–IV) [94]. Astrocytomas grade IV are
also called glioblastoma multiforme (GBM), and accounts for 60–
70% of all malignant gliomas [94,95]. GBM is one of the most
heterogeneous and aggressive forms of brain tumor, with a poor
prognosis [96]. These characteristics might increase chance of
recurrence in patients with GBM. Currently, surgery, radiothera-
py, and chemotherapy are the common treatment options for
GBM [97]. However, different signal transductions and TKIs are
now being evaluated in clinical trials.
There are several preclinical studies investigating different pu-
tative therapeutic targets in glioma. For example, patients with
GBM with EGFR mutations and amplifications have poorer prog-
nosis compared with patients with wild-type EGFR. Knockout of
either wild-type or mutant (EGFRvIII) EGFR resulted in the inhibi-
tion of tumor growth in human glioma U87 and LN229 cells as
well as in mice [98]. Thus, complete inhibition of EGFR could be a
promising therapeutic option for patients with GMB. However,
more detailed studies and confirmations are needed.
Targeting key players of any activated pathway in cancers is
predicted to have inhibitory effects on tumor cells. Based on the
pathway, it might influence cell proliferation, invasion, and mi-
gration abilities. STAT3 activation, ranging from 9% to 83%, has
been reported in patients with glioma, probably because of differ-
ences in tumor grade [99,100]. A positive correlation has been
shown between STAT3 activation levels and glioma grades, sug-
gesting a crucial role for this protein in tumor invasiveness and
possibly distant metastasis [101]. Inducing CRISPR-mediated loss-
of-function mutations in STAT3 strongly inhibited GBM tumori-
genesis in vivo in mice. Moreover, glioma-initiating cells (GICs)
were highly addicted to STAT3 and were not viable upon STAT3
depletion [102]. A recent preclinical study also showed that the
AK2/STAT3 inhibitor pacritinib strongly inhibited patient-derived
GBM cells [103]. Based on these results, inactivation or inhibition
of STAT3 by either gene manipulation or chemical compounds,
especially during early disease stages, could be beneficial for
patients with GBM.
Liu et al. investigated the role of ERb isoforms in the progression
of GBM using CRISPR-mediated knockout in patient-derived GBM
cells. Disruption of ERb increased migratory and invasive proper-
ties of the glioma cells. The authors revealed tumor suppressor
activity of ERb1 in GBM cells, whereas ERb5 had more oncogenic
effects and its restoration increased cell viability. They also identi-
fied significantly higher expression of ERb5 in glioma tumors
compared with normal brain tissues, with the highest expression
in GBM [104]. Thus, anti-ERb5 drugs could be prescribed as a
therapeutic strategy in patients with high-grade glioma in the
future.
The CRISPR/Cas9 knockout system has frequently been used to
elucidate the role of different proteins in glioma pathogenesis.
Peng and colleagues investigated the role of chromatin assembly
factor 1 subunit A (CHAF1A) in glioma cell survival. Loss of
CHAF1A significantly increased apoptosis and caused cell cycle
arrest in two GBM cell lines (U251 and U87). They also observed
that expression of CHAF1A was negatively associated with overall
survival of patients with GBM [105], similar to a previous study on

















Wcolon cancer [106]. Therefore, suppression of CHAF1A in patients
might prolong their overall survival. Disruption of brain lipid-
binding protein (BLBP) resulted in the inhibition of cell prolifera-
tion in U251 GBM cells. Furthermore, higher expression of BLBP
was associated with poorer clinical outcome in patients with GBM
[107]. In another study, depletion of polo-like kinase 1 (PLK1) in
mouse model brain tumors improved survival and significantly
inhibited tumor growth [108]. Interestingly, several PLK1 inhibi-
tors, including BI-2536, GSK461364, and volasertib, are currently
in clinical trials for the treatment of other solid tumors, but not
gliomas [109]. Inhibition of all the genes and proteins discussed
could be beneficial for patients and improve clinical outcomes.
However, further preclinical and clinical studies are warranted
before such approaches enter the clinic.
There arealso some reportsshowing that loss-of-function changes
inseveralncRNAscanbea promisingtreatment approachinpatients
with GBM. CRISPR-mediated knockout of the lncRNA MANTIS
resulted in an 50% reduction in angiogenic capacity of the endo-
thelial cells isolated from GBM and attenuated tube formation.
These data showed that the angiogenic capacity of endothelial cells
is dependent on MANTIS [110], which could be exploited to impair
angiogenesis in tumors. In addition, disruption of miR-10b in GBM
cells revealed their strong addiction to this miRNA. It impaired cell
viability andresulted in the upregulation of miR-10b verified targets,
includingcell-cycleinhibitorP21and themediatorofapoptosisBIM.
Disruption of miR-10b was lethal both in vitro and in vivo. Interest-
ingly, miR-10b was overexpressed in patients with GBM, which
makes it a suitable target in gliomas [93]. Thus, suppression of such
ncRNAs with oncogenic activity could significantly inhibit tumor
growth in patients with glioma.
As discussed above, CRISPR-based preclinical studies have
shown promising results in the treatment of gliomas. Several
genes, including those encoding kinases, have been shown to
have oncogenic roles in glioma, which could be exploited to target
tumor cells in a subset of patients. However, further clinical studies
are needed to validate these candidate targets.
Liver cancer
Primary liver cancer is the second cause of cancer-related death in
the world and is more common in men. Primary liver cancer is
divided into two main subtypes: hepatocellular carcinoma (HCC)
and intrahepatic cholangiocarcinoma (ICC). HCC and ICC ac-
count for 80% and 15% of the total cases, respectively. The
remaining 5% are the rare subtypes of liver cancer [111]. Most
patients with liver cancer have a poor prognosis, frequent recur-
rences, and limited treatment options. Therefore, CRISPR/Cas9
technology could be a promising approach to identify new thera-
peutic targets in this cancer [112].
CXC chemokine receptor 4 (CXCR4) expression levels have
significant negative correlation with clinical outcomes in patients
with HCC [113]. CRISPR-mediated ablation of CXCR4 in HepG2
cells resulted in suppressed cell proliferation and migration. More-
over, CXCR4 attenuation resulted in a smaller tumor size in vivo
[114]. Thus, CXCR4 has an oncogenic role in HCC and could be
used as a treatment target to control growth or distant metastasis.
Several other potential targets in HCC have been investigated by
using CRISPR/Cas9. For example, simultaneous CRISPR-based
knockout of Pten and overexpression of Nras led to HCC formationin vivo, whereas single gene manipulation did not result in tumor-
igenesis. Aberration in the expression of Pten or Nras is necessary
for liver tumorigenesis, but it is not sufficient if these changes are
not present simultaneously [115]. Therefore, inhibition of over-
expressed NRAS in patients with PTEN loss might suppress tumor
growth and improve patient survival a subset of HCCs. Nuclear
receptor coactivator 5 (NCOA5) encodes a coregulator for ERs and
is dysregulated in several types of cancer. Genetic knockout of
NCOA5 significantly inhibited cell growth and migration in HCC
cells. In addition, loss of the NCOA5 protein substantially sup-
pressed EMT, which is a common drug resistance mechanism in
different cancer types [116]. Nogo-B is a negative regulator of
apoptosis [117] and its CRISPR-based deletion led to significant
inhibition of cell proliferation in vitro as well as suppression of
tumor growth and distant metastasis in vivo [118]. All the afore-
mentioned genes could be considered as appropriate therapeutic
candidates for further in vivo studies or clinical trials as inhibitors
are developed.
Hepatitis B virus (HBV) is one of the pathogens for HCC, and
HBV infection can lead to HCC. One of the potential therapeutic
applications of CRISR/Cas9 system is to prevent HBV-derived liver
cancer by destroying viral DNA. HBV particles contain relaxed
circular DNA (rcDNA), which is converted to covalently closed
circular DNA (cccDNA) upon entering hepatocytes. cccDNA serves
as template for all HBV transcripts. Thus, elimination of cccDNA,
for instance by cleaving, could cure HBV. Several preclinical
studies targeting HBV have shown promising results that might
be beneficial to eradicate HBV as one of the main risk factors for
liver cancer. Lin and colleagues used CRISPR/Cas9 technology
against HBV. Using a gRNA targeting a conserved HBV genomic
region, production of EBV surface and core proteins was success-
fully suppressed both in vitro and in vivo. The authors also effi-
ciently reduced rcDNA and cccDNA levels in the cells [119].
Another research group showed that HBV-specific gRNA combina-
tions reduced HBV DNA and cccDNA up to 1000- and tenfold in
vitro, respectively [120]. Li et al. used the CRISPR/Cas9 system to
successfully eradicate HBV infection from HBV-positive HepG2
cells by deleting the entire integrated HBV genome and disruption
of cccDNA [121]. Similar results were reported by other groups
[122–124]. In addition, CRISPR-based ablation of flap structure-
specific endonuclease 1 (FEN1) in Hep38.7-Tet, an in vitro HBV
model, resulted in reduced cccDNA levels, suggesting a crucial role
for the host FEN1 protein in cccDNA production [125].
Colorectal cancer
Colorectal cancer is one of the most frequent types of cancer and
the fourth cause of cancer-related death worldwide [126]. Adeno-
carcinoma (ADC) accounts for >90% of all colorectal carcinomas.
The remaining 10% are rare subtypes, including adenosquamous,
squamous cell, neuroendocrine, spindle cell, and undifferentiated
carcinomas. Approximately 95% of colorectal cases are sporadic
and 5% are inherited. Colorectal tumors can be triggered by driver
mutations in well-known cancer genes, such as KRAS and BRAF, in
40% and 10% of patients, respectively. Treatment of patients is
based on histology and molecular testing, but, similar to other
cancers, tumors eventually become resistant to treatment [127].
Therefore, overcoming resistance by the identification of new
therapeutic targets is crucial.www.drugdiscoverytoday.com 961












IEWYau et al. used genome-wide CRISPR/Cas9 screening of KRASmut
and KRASwt colorectal cancer xenografts to identify genes that pro-
mote or suppress tumor growth in vivo. They showed that disruption
of NAD kinase (NADK) or ketohexokinase (KHK) significantly inhib-
ited KRASmut tumor xenografts compared with KRASwt xenografts,
suggesting them as potential therapeutic targets in KRAS-driven
colorectal tumors [128]. Several NADK and NHK inhibitors have
been synthesized [129,130]. However, preclinical and clinical studies
are needed to evaluate their efficacy and toxicity in human cells.
Caspase-3 (CASP3) is involved in apoptosis and its higher activ-
ity is associated with a higher risk of tumor relapse in colon cancer
[131]. It is overexpressed in colorectal cancer primary tissues and
its higher expression is significantly associated with shorter overall
survival [132]. CRISPR-mediated knockout of CASP3 in a colon
cancer cell line (HCT116) significantly attenuated cell tumorigen-
esis, invasion, and migration. Interestingly, deletion of CASP3
resulted in the higher sensitivity of the cells to radiotherapy both
in vitro and in vivo [133]. Together, these data suggest that inhibi-
tion of caspase-3 could be used to improve clinical outcome in
patients with colon cancer.
NAT1 is a member of the N-acetyltransferases family and is
associated with cancer cell proliferation [134]. In addition,
NAT1 can protect colon cancer cells during nutrient deprivation,
and its absence is lethal [135,136]. Genetic ablation of NAT1 in HT-
29 colon cancer cells suppressed cell growth and promoted apo-
ptosis under glucose starvation by enhanced production of reac-
tive oxygen species (ROS) [134]. Thus, inhibition of NAT1 in
combination with specific diets could be an effective method to
treat colon cancer. A study by Nishi et al. revealed that production
of ROS significantly reduced expression of a protein called NHL-
repeat-containing protein 2 (NHLRC2), resulting in increased
levels of apoptosis in HCT116 colon cancer cells. They showed
that genetically engineered NHLRC2/ cells were more suscepti-
ble to ROS-induced apoptosis [137], which might have potential
therapeutic benefits for patients with colorectal cancer.
Dysregulation in autophagy is known to be involved in cancer
pathogenesis [138]. For instance, MARCH2 is involved in the
regulation of autophagy [139]. CRISPR/Cas9-based disruption of
MARCH2 attenuated cell proliferation, while promoting apoptosis
and cell cycle arrest in colon cancer cells both in vitro and in vivo.
Further investigations on primary tumor samples revealed higher
expression of MARCH2 compared with normal tissue. Moreover,
higher expression of this protein was significantly associated with
poorer overall survival in patients [140]. Therefore, either genetic
disruption or chemical inhibition of MARCH2 could improve
clinical outcomes in a subset of patients with colon cancer.
Application of CRISPR/Cas9 genome-editing technology has led
to the identification of several other candidate targets in colorectal
cancer. For example, deletion of the RNA-binding protein ELAVL1
(HuR) in colorectal cancer cells resulted in a significant reduction in
tumor growth compared with the control group in vivo. The authors
also revealed that ELAVL1 is substantially overexpressed in colon
primary tumors, which makes it a suitable therapeutic candidate
[141]. Wu et al. knocked out RBX2, a component of E3 ubiquitin
ligases, in two colon cancer cell lines to investigate its role in
tumorigenesis. RBX2/ cells showed significantly reduced colony
formation and migration capacity in vitro. In addition, abrogation of
RBX2 significantly reduced tumor size and lung metastasis in vivo.962 www.drugdiscoverytoday.comFurther investigations using colorectal primary tumors revealed a
higher expression of this protein compared with normal tissues
[142]. Thus, RBX2 appears to be a suitable target in patients with
overexpressed RBX2 to prevent, or at least delay, distant metastasis,
which is the main cause of death in all cancer types.
Similar to other types of cancer, ncRNAs have an important role in
colon tumorigenesis. It has been demonstrated that a small nucleo-
lar RNA, calledSNORA21, has an oncogenic role in colorectal cancer.
CRISPR-based ablation of SNORA21 resulted in substantial suppres-
sion of cell proliferation, invasion, and tumor growth capacities
both in vitro and in vivo. The authors also revealed a significantly
higher expression of SNORA21 in primary colon tumors compared
with normaltissues. Inaddition, theyshowedthathigher expression
of SNORA21 was negatively correlated with overall survival, disease
stage and distance metastasis [143]. Thus, SNORA21 could be a
potential therapeutic target and its inhibition could be beneficial
for patients with high-stage colorectal tumors.
CRISPR/Cas9 delivery to cancer cells
Delivery of nucleases, such as Cas9, ZFN, and TALENs, remains one
of the most substantial challenges to the use of such therapy in the
clinic. With rapid developments of CRISPR-based techniques, it is
crucial to develop more efficient, precise, and accurate delivery
methods. All nucleases, including the meganucleases, Cas9, ZFN,
and TALENs, are biomacromolecules and have similar challenges
to their delivery into human cells. Despite different components
and characteristics, all nucleases can be generally delivered in the
format of DNA, mRNA, or protein. The only difference in the
CRISPR/Cas9 system is that the gRNA should be delivered as DNA
or RNA molecules compared with the other nucleases [144–146].
There are two types of gene delivery system: viral and nonviral
vectors. For basic research, for instance, the identification of gene
function and identification of novel therapeutic targets, diverse
categories of viral or nonviral delivery methods can be used.
Recently, nonviral delivery techniques, such as electroporation,
hydrodynamic injection, microinjection, and self-assembled
nanoparticles (NPs), were used in ex vivo gene-editing using
nucleases [147,148]. Yet, ex vivo gene editing with NPs and inte-
gration of a viral system cannot be used in most tissues types
because of low efficiency and safety concerns [149].
Viral vectors are more effective and attractive for the delivery of
CRISPR/Cas9 in vivo. Compared with traditional non-integrated
viral-based gene therapy, in which continuous transgene expres-
sion is needed by repeated dose, permanent genome editing can be
achieved by transient expression of CRISPR/Cas9 with a single
administration. Given that CRISPR/Cas9 has shown high levels of
efficiency, specificity, and stability, requirements of the viral
vectors for delivery of CRISPR/Cas9 might not be as strict as
previously required. The preferred viruses for the delivery of
nucleases are AdVs, integrase-defective lentiviruses (IDLV), and
adeno-associated viruses (AAVs) [150–152]. Here, we provide an
overview of appropriate viral and nonviral vectors used for the
delivery of nucleases in cancer cells.
Viral vectors
AdVs and AAV vectors
AdV and AAV vectors have been extensively studied for the delivery
of different nucleases in vitro, ex vivo, and in vivo because of their high

















Wtiter, relatively mild immune response, a broad range of cell infec-
tivity, and safety. One study showed that ZFNs can be expressed
more efficiently using AdV vectors compared with IDLV in geneti-
cally engineered primary T cells [153]. More importantly, modified
AdV vectors showed more accuracy and specificity than IDLV for
donor DNA delivery [153]. However, host inflammatory responses,
including cytotoxic T cells, limits AdV vector application [154]. The
other drawback is the expression level of coxsackie-adenovirus
receptor (CAR) on the tumor cell surface, which determines the
efficiency of delivery using AdV vectors. The CAR expression level
has a negative correlation with tumor grade. Thus, AdV is not
efficient for the delivery of nucleases directly to high-grade tumors.
Recombinant AAVs (rAAVs) are also attractive options for the
delivery of nucleases. They are commonly used in the delivery of
ZFNs, TALENs, and CRISPR/Cas9, because AAV vectors have the
ability to avoid random integration and show low immunogenic
characteristics [152,155–158]. The low packaging capacity
(4.7 kbp) is the main limitation of AAV vectors. Therefore, the
recombinant sequence needs to be carefully designed to match the
AAV capacity.
LV and IDLV vectors
Self-inactivating lentiviral vectors (LVs) are commonly used as
vehicles for gene therapy in dividing and nondividing cells
[159–161]. After decades of preclinical and clinical testing, LVs
are being used to treat a variety of genetic diseases, such as X-
linked adrenoleukodystophy and Wiskott–Aldrich syndrome
[160,162–164]. Currently, several studies have shown that LVs
can be used to efficiently deliver CRISPR/Cas9 to mammalian cells
and mice for cancer gene therapy [165–167]. However, unlike
using LVs for gene replacement therapy, the continuous expres-
sion of Cas9 is unnecessary and might be a problem.
Compared with integrating LVs, IDLVs minimize proviral inte-
gration because of mutations in the integrase protein, which make
it more suitable for the delivery of CRISPR/Cas9 [151,166]. IDLVs
have been successfully used to deliver CRISPR/Cas9 and its donor
template in vitro. Approximately 6–11% gene knock-in was
achieved in hematopoietic stem and progenitor cells (HSPCs)
[168]. IDLVs have also been used to codeliver ZFNs/TALENs and
HDR donor templates into a variety of cell types, including prima-
ry and stem cells, with a relatively high efficiency (>20%). How-
ever, IDLV-mediated gene editing can cause undesired gene
modifications, such as epigenetic silencing and the induction of
genomic rearrangements, particularly in repetitive sequence loci.
Another disadvantage is that IDLV-mediated Cas9 delivery leads to
a higher off-target effect in quiescent or slowly dividing cells, such
as hepatocytes and neurons [169].
Nonviral vectors
Nonviral vectors are being rapidly developed and several nonviral
vectors, including lipid-based vectors and polymer-based vectors,
are widely used in gene therapy [170]. Unlike viral vectors, the
capacity of nonviral vectors is flexible. In addition, it appears that
many disadvantages of viral vectors, such as mutagenesis and
immunogenicity, can be addressed by using nonviral vectors
[170–172]. Lower immunity or absence of pre-existing immunity
in patients is an important advantage of nonviral vectors over viral
vectors. However, compared with viral vectors, some nonviral
vectors are not able to penetrate cells efficiently, resulting inlow levels of gene transfer efficiency and high in vivo toxicity,
which could limit their use of in clinical trials [16].
In recent years, nonviral vectors have been used for CRISPR/
Cas9 delivery in vitro and in vivo. For instance, one study showed
that up to 80% gene modification can be achieved in vitro using
cationic liposomes. In addition, cationic liposomes have been
successfully used to deliver CRISP/Cas9 to the inner ear in mouse
models [172]. Another study successfully used polyethylenimine
(PEI) for the delivery of CRISPR/Cas9 to mouse brain [173].
Combined viral and nonviral delivery
A recent study showed that the combined use of viral and nonviral
vectors (lipid-based vectors and AAVs) achieved >6% gene repair
(HDR) in hepatic cells [174]. They also applied this approach to a
mouse model and successfully repaired the disease-causing gene.
This method might be an efficient option for the delivery of
CRISPR/Cas9 to patients.
Tissue- or tumor-specific delivery of CRISPR/Cas9
Several studies have shown that CRISPR/Cas9 is capable of editing
genes with high accuracy and efficiency [19,175,176]. However,
for cancer gene therapy, how to specifically deliver CRISPR/Cas9 to
cancer cells is still a major obstacle. Herein, we briefly explain some
of these delivery methods, including the use of appropriate viral
serotypes, specific promoters, and bispecific conjugates.
More than 200 AAV serotypes have been identified so far.
Packaging CRISPR/Cas9 into the appropriate AAV serotype for
tissue-specific delivery is a promising strategy for cancer gene
therapy. Several rAAV vectors have been developed for clinical
trials and, recently, the first gene therapy for treatment of an
inherited retinal disease using AAV was approved by the US Food
and Drug Administration (FDA) [177]. One study showed that
CRISPR/Cas9 delivery using AAV serotype 9 (AAV9) was highly
efficient for tissue-specific delivery and did not cause substantial
cellular damage in vivo [178].
Utilizing a promoter-based ‘AND’ logic gate can control CRISPR/
Cas9 to be specifically expressed in bladder cancer cells [179]. The
strategy of promoter-based logic gates, including ‘AND’, ‘OR’, and
‘NOT’, have the potential to create more complex and precise
regulatory patterns that can be conditionally expressed. Delivery
of CRISPR/Cas9 to tumor cells with such precision could accelerate
the use of CRISPR-based cancer gene therapy from bench to bedside.
Low expression of CAR on the tumor cell surface and lack of
specific receptors significantly limits the clinical use of AdV vectors
in cancer gene therapy. However, redirecting AdV vectors to
tumor-specific cell surface target receptors, such as EGFR, EpCAM,
CD40, PDGF-Rbeta, and VEGFR, can selectively target tumors,
which may improve the specificity and efficiency of AdV simulta-
neously [180–183].
CRISPR/Cas9; hopes and challenges in cancer
treatment
CRISPR/Cas9 genome-editing technology has shown promising
results in preclinical studies. It is a convenient tool that has
enabled researchers to perform gene manipulation at a single
base-pair resolution in a relatively efficient way. Preclinical studies
have led to the identification of several potential therapeutic
targets by using CRISPR-based methods (Table 3). This has broughtwww.drugdiscoverytoday.com 963
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identified by using CRISPR/Cas9 genome-editing technologiesa
Vector Effect Refs
f mutant allele AdV Promoted cell death and reduced tumor
size
[4]
f mutant allele LV Reduced cell proliferation and tumor size [43]
s knockout LV Reduced cell proliferation [44]
s knockout Nonviral Inhibited cell growth and invasion [48]
s knockout Nonviral Reduced cell proliferation and tumor size [50]
s knockout LV Dual knockout inhibited cell proliferation,
cancer stem cell sphere formation, and
tumor formation
[54]
s knockout LV Suppressed MYC expression and inhibited
cell growth
[55]
diated gene LV Enhanced metastatic potential of cells [61]
s knockout LV Induced tumor development, but
attenuated disease progression in vivo over
time
[34]
diated gene LV Promoted cell migration and invasion [68]




LV Impaired lodging of cancer cells to mouse
bone and reduced number of cancerous
lesions in each animal
[73]
s knockout Nonviral Promoted apoptosis and inhibited tumor
growth and distant metastasis
[74]
s knockout Nonviral Inhibited cell proliferation, migration,
tumor size, and rate of lung metastasis
[75]
s knockout Nonviral Inhibited cell proliferation and migration [79]
s knockout LV Inhibited cell migration, invasion, and
tumor growth
[80]
s knockout LV Impaired cell proliferation and tumor
growth
[83]
s knockout LV Dual knockout inhibited cell proliferation
and tumor growth
[84]
s knockout LV Inhibited cell proliferation and impaired
cell viability
[87]





LV Suppressed cell proliferation, migration,
and tumor formation
[69]
s knockout Nonviral Inhibited cell proliferation and tumor
growth
[92]
s knockout LV Suppressed cell migration [93]
f both wild-type
t (EGFRvIII) EGFR
LV Inhibited cell proliferation and tumor














List of (potential) therapeutic targets in different solid tumors 
Target in vitro Cell line in vivo CRISPR 
Lung cancer
EGFR + H1975 + Knockout o
(L858R)
EGFR + H1975 + Knockout o
(L858R)
KRAS + A549 and KP-KrasG12D/1
(mouse lung cancer cells)
+ Both allele
CD38 + A549 + Both allele
FAK + H460 + Both allele
TAZ and YAP + A549 + Both allele
MUC1 + A549 and H460  Both allele
Tnc + Collection of cell lines
isolated from mice with




Smarca4  – + Both allele
mir-323b, mir-487a
and mir-539
+ H2009  CRISPR-me
activation
Breast cancer
Mlk3 + 4T1 (murine breast
cancer cells)
+ Both allele
CX3CR1 + MDA-MB-231 + CRISPR-bas
suppressio
interferenc
Ubr5 + 4T1 (murine breast
cancer cells)
+ Both allele
CXCR2 + MDA-MB-231 + Both allele
MARK4 + MDA-MB-231  Both allele




MASTL + MDA-MB-231, MCF7,
BT549, and BT-483
+ Both allele
PTPN23 and FYN + Cal-51 + Both allele
CDK7 + MDA-MB-231, MDA-MB-
468, HCC38, BT549, and
SUM149
+ Both allele
SHCBP1 + MDA-MB-231 and MCF7  Both allele
PHF5A + CA1a and DCIS + CRISPR scr
RNA-bindin
lnc BC200 + MCF7 + Both allele
miR-10b + MDA-MB-231  Both allele
Glioma
EGFR + U87 and LN229 + Knockout o
and mutan964 www.drugdiscoverytoday.com
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TABLE 3 (Continued )
Target in vitro Cell line in vivo CRISPR Vector Effect Refs
STAT3 + MT330 + Both alleles knockout LV Inhibited tumorigenesis in vivo, but limited
effect on cell proliferation in vitro
[102]
ERb + U87 and U251 + Both alleles knockout of ERb
followed by reintroduction
of ERb1 and ERb5
separately
Nonviral/LV ERb knockout elevated migratory and
invasive properties. Overexpression of
ERb5 enhanced cell migration and
invasion
[104]
CHAF1A + U87 and U251  Both alleles knockout LV Inhibited cell proliferation, increased
apoptosis, and caused cell cycle arrest
[105]
BLBP + U251  Both alleles knockout LV Inhibited cell proliferation and caused cell
cycle arrest
[107]
PLK1 NA NA + Both alleles knockout Nonviral Inhibited tumor growth and improved
survival
[108]
lncRNA MANTIS Ex vivo Endothelial cells isolated
from GBM
+ Both alleles knockout Nonviral Reduced angiogenic capacity of cells and
suppressed tube formation
[110]
miR-10b + U251, LN229, and A172 + Both alleles knockout LV Impaired cell viability, enhanced expression




CXCR4 + HepG2 + Both alleles knockout Nonviral Inhibited cell proliferation and migration
and reduced tumor size
[114]
Pten and Nras  – + Both alleles knockout and
CRISPR-mediated gene
activation
Nonviral Simultaneous knockout of Pten and
activation of Nras led to liver tumorigenesis
[115]
NCOA5 + LM3  Both alleles knockout LV Inhibited cell proliferation and migration,
suppressed tumor formation and EMT
[116]
Nogo-B + SMMC-7721 and QGY-
7703
+ Both alleles knockout Nonviral Inhibited cell proliferation and suppressed
tumor growth and distant metastasis
[118]
Colorectal cancer






LV Inhibited KRASmut tumor growth [128]
CASP3 + HCT116 + Both alleles knockout NA Suppressed EMT and attenuated cell
tumorigenic, invasion, and migration
abilities
[133]
NAT1 + HT-29  Both alleles knockout Nonviral Inhibited cell growth and promoted
apoptosis under glucose starvation
[134]
NHLRC2 + HCT116  Both alleles knockout LV Inhibited cell proliferation and promoted
apoptosis
[137]
MARCH2 + HCT116 + Both alleles knockout NA Inhibited cell proliferation, promoted
apoptosis and cell cycle arrest, reduced
tumor size
[140]
ELAVL1 + HCT116 + Both alleles knockout Nonviral Suppressed tumor growth [141]
RBX2 + HCT116 and SW480 + Both alleles knockout Nonviral Inhibited colony formation and cell
migration capacity, reduced tumor size and
lung metastasis
[142]
SNORA21 + HCT116 and SW48 + Both alleles knockout LV Suppressed cell proliferation, invasion and
tumor growth
[143]

















Whope for the therapeutic application of this technology in cancer
treatment. However, there are some concerns regarding its appli-
cation in the clinical setting. Here, we have mainly discussed genes
with oncogenic activities because gene knockout is more conve-
nient compared with gene knock-in using CRISPR/Cas9 (Fig. 2). In
addition, oncogenes are usually overexpressed in primary tumors
and are more amendable to pharmaceutically inhibition.Although malignant tumors are genetically heterogeneous, tu-
mor bulk is mainly the result of outgrowth of one or two dominant
clones [184] caused by driver mutations in certain genes. sgRNAs can
distinguish between mutant and wild-type alleles in tumor cells,
reducing off-target effects and improving the specificity [185].
Therefore, hotspot driver mutations in genes such as EGFR, KRAS,
BAP1, BRAF, BRCA1, and BRCA2 can be exploited as a therapeuticwww.drugdiscoverytoday.com 965
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IEWapproach at least in a subset of patients. One of the main advantages
of thisstrategy is that normalcells, donot containthe mutantalleles,
are not targeted and, thus, remain intact. In addition, mutations in
oncogenes such as KRAS are indicators of drug resistance and poor
prognosis in a subgroup of patients with NSCLC, including Asians or
women with low-grade tumors [186]. By contrast, CRISPR/Cas9 can
precisely target a specific locus in the genome. Therefore, substitut-
ing KRAS mutant versions (p.G12V and p.G12D) with the wild-type
allele could positively improve treatment response in KRAS-depen-
dent cancers.
Series of CRISPR-associated nucleases have been discovered over
the past few years that can greatly facilitate genome editing.
However, there are still some major problems that need to be
solved before CRISPR/Cas9 enters the clinic, such as off-target
effects [187], continuous activity of Cas9 [187], low efficiency of
current delivery systems [187], low efficiency of CRISPR/Cas9-
mediated gene knock-in [168], pre-existing adaptive immunity
[187], and uncontrollable DNA repair [187]. In addition, recent
studies have shown that p53 can inhibit CRISPR/Cas9 gene-editing
efficiency [188,189]. According to these studies, CRISPR/Cas9
tends to target cells with intact p53, leaving behind p53-deficient
cells, which have the potential to become cancerous. Thus, evalu-
ation of p53 protein before and after gene editing for the treatment
of the patients is crucial. However, CRISPR-induced p53 activation
appears to occur only during gene editing by HDR. The base editors
probably will not trigger p53 and, thus, are safer in this regard
compared with CRISPR/Cas9 technology.
Selection of the right target is an important step towards devel-
oping a new treatment strategy. A candidate protein and/or mole-

























































Potential therapeutic clustered regularly interspaced short palindromic repe
option for cancer gene therapy is the disruption of oncogenes rather than 
mutated genes in different cancers based on the COSMIC database (v87). M
frequency based on sample size across all studies. This figure contains mod966 www.drugdiscoverytoday.comits higher expression in primary tumor tissues. Extensive function-
al in vitro and in vivo studies are required before proceeding to a
clinical trial. For example, FOXC, a transcription factor, is consid-
ered as prognostic biomarker in breast cancer and has been sug-
gested as a therapeutic target [190,191]. However, a recent study by
Mott and colleagues showed no difference in tumor size and
metastasis between FOXC1/ and parental tumor cells in vivo
[192]. Similarly, one recent thought-provoking study showed that
maternal embryonic leucine zipper kinase (MELK) is not a cancer
target, whereas multiple ongoing clinical trials are trying to inhibit
MELK to treat cancer [193]. These results highlight the importance
of in vivo studies using CRISPR/Cas9 in the validation of biomark-
ers and therapeutic targets and their reliability.
Overall, there are four steps to bring a protein or molecule as a
therapeutic approach from the bench to the clinic: (i) identifica-
tion of key molecules in different diseases; (ii) validation of those
molecules by in vitro and in vivo studies; (iii) development of an
efficient method to inhibit that specific molecule; and (iv) suc-
cessful Phase I–III clinical trials. If any of these steps fails, new
therapeutic approaches will not be able to enter into clinics.
The low rate of all-alleles knockout in cancer cells is another
important challenge that has to be taken into account. This is
caused by the high amount of aneuploidy in cancer cells, which
can result in an unpredictable outcome [194]. Therefore, the
application of multiple gRNAs for a certain gene can increase
the chance of all-alleles knockout in cancer cells. However, this
strategy might lead to a subpopulation of cells with active alleles
resulting from an in-frame repair of DSB in the target site induced
by several gRNAs. In addition, not all gRNAs have the same
efficiency; some are more active than others. One solution is to

















Wcarefully design and evaluate each gRNA in vitro and in vivo for
certain types of cancer cell and then choose the most efficient
combinations. This can reduce the number of gRNAs for a certain
gene while increasing the efficiency of the technique. Interesting-
ly, the distance between different gRNAs can also influence the
knockout efficiency. It has been shown that multiple carefully
designed adjacent gRNAs can improve the chance of having cells
with complete gene knockout [195]. In addition, HDR is active in S
and G2/M phases, but DSB repairs occur more in G0/G1. Thus,
using cytostatic drugs to introduce cell cycle arrest might regulate
the repair process in a certain extent [188,189]. In addition, new
versions of Cas9, such as Cpf1, are able to generate staggered DSBs,
which might result in more accurate and precise repairs [23].
Efficiency of the delivery methods to cancer cells remains one of
the biggest challenges in the application of CRISPR/Cas9 as a
therapeutic tool in cancer treatment. More specific and efficient
delivery vectors need to be developed to achieve sufficient levels of
transduction and transgene expression. Traditional virus delivery
approaches, such as AdV, LV, and AAV, are currently not sufficient
enough to reach clinical requirements for delivery, especially in
targeting cancer cells. Therefore, using CRISPR/Cas9 to improve
currently available treatment strategies appears more realistic. For
instance, engineered universal CAR-T cells by CRISPR/Cas9 can
improve antitumor efficacy (Table 1). In addition, CRISPR/Cas9
can be utilized to resensitize drug-resistant tumor cells and
improve the treatment response by deleting and/or modifying
resistance-related genes. Finally, arming oncolytic viruses with
CRISPR/Cas9 could be a new approach to treat cancers [196].Another attractive application of CRISPR/Cas9 is to improve
programmed cell death protein 1 (PD-1)-associated immunothera-
pies. CRISPR-based disruption of PD-1 in T cells significantly
suppresses expression of PD-1 and promotes the cellular immune
response in vitro [197]. An ongoing Phase I clinical trial in China is
using CRISPR-engineered T cells to investigate the safety and
efficiency of this immunotherapy-based treatment in patients
with metastatic NSCLC [198]. In this method, peripheral T cells
of the patients are collected, PD-1 is knocked out by CRISPR/Cas9,
and cells are reinfused to the patients. The engineered T cells
escape suppression by PD-L1-positive tumor cells and can perform
their antitumor activity [199]. This type of combination therapy,
especially combining CRISPR/Cas9 with CAR-T- or PD-1-associat-
ed trials (Table 1), could improve outcomes of clinical cancer
treatment in the near future.
Concluding remarks
In conclusion, CRISPR/Cas9 genome-editing technology has led to
the identification of several potential therapeutic targets in differ-
ent malignancies. However, the use of CRISPR/Cas9 as a treatment
option in cancer involves several issues, such as minimizing off-
target effects, immunological responses to Cas9, validation of
therapeutic targets in animal models, and optimization of the
delivery methods, which have to be addressed before entering into
use in the clinic. Despite all the above-mentioned challenges,
CRISPR/Cas9 has brought invaluable opportunities in the field
of cancer gene therapy and could have a crucial role in cancer
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